Clinical Trials Support Core The Clinical Trials Support Core (CTSC) is a shared resource available to all members of the HCCC. It is designed to facilitate execution of high quality clinical cancer investigation including both interventional and correlative science studies. The CTSC enhances interaction among HCCC members and provides for easy assembly of multi-departmental teams needed for collaboration on innovative protocols. The CTSC is composed of dedicated staff with expertise in protocol management and study coordination. Administratively, the Director of the CTSC works closely with the Assistant Director for Clinical Services, and reports to the Associate Director for Clinical and Translational Research. The CTSC provides investigators with appropriate routing of protocols through the various internal regulatory committees including the HCCC Protocol Review and Monitoring Committee, assists the investigator in protocol modifications and reporting of adverse events for ongoing clinical studies, and supplies staff with expertise in data management. The CTSC also provides support for translational research by assisting in the procurement of blood and other not surgical tissues for investigators. It participates in posting protocol lists and supporting internal communication regarding ongoing studies, as well as statistical reporting on accrual. A chargeback system is used to compensate the CTSC for support of most clinical trials run through the CTSC. The core also supports innovative, early phase clinical trials for which there is no other source of support.
The Clinical Trials Support Core provides a centralized resource for investigators interested in clinical and translational cancer research. It is a vital shared resource if we are to translate basic science advances in cancer to the clinic.
|Machiela, Mitchell J; Lan, Qing; Slager, Susan L et al. (2016) Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Hum Mol Genet 25:1663-76|
|Fink, Aliza K; Yanik, Elizabeth L; Marshall, Bruce C et al. (2016) Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros :|
|Mambetsariev, Nurbek; Lin, Wai W; Stunz, Laura L et al. (2016) Nuclear TRAF3 is a negative regulator of CREB in B cells. Proc Natl Acad Sci U S A 113:1032-7|
|Vander Weg, Mark W; Cozad, Ashley J; Howren, M Bryant et al. (2016) An individually-tailored smoking cessation intervention for rural Veterans: a pilot randomized trial. BMC Public Health 16:811|
|Schroeder, Mary C; Chapman, Cole G; Nattinger, Matthew C et al. (2016) Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study. BMC Health Serv Res 16:274|
|Brooks, Jennifer D; John, Esther M; Mellemkjaer, Lene et al. (2016) Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer. Cancer Med 5:3282-3291|
|Craciun, Ioana; Fenner, Amanda M; Kerns, Robert J (2016) N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3. Glycobiology 26:701-9|
|Wang, Bingxuan; Klaren, William D; Wels, Brian R et al. (2016) Dietary Manganese Modulates PCB126 Toxicity, Metal Status, and MnSOD in the Rat. Toxicol Sci 150:15-26|
|Klaren, William D; Gibson-Corley, Katherine N; Wels, Brian et al. (2016) Assessment of the Mitigative Capacity of Dietary Zinc on PCB126 Hepatotoxicity and the Contribution of Zinc to Toxicity. Chem Res Toxicol 29:851-9|
|Safaeian, M; Robbins, H A; Berndt, S I et al. (2016) Risk of Colorectal Cancer After Solid Organ Transplantation in the United States. Am J Transplant 16:960-7|
Showing the most recent 10 out of 463 publications